Rhumbline Advisers Pliant Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 94,697 shares of PLRX stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,697

Previous 96,488 1.86%

Holding current value

$1.23 Million

Previous $1.04 Million 2.31%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$10.52 - $14.35 $18,841 - $25,700	-1,791 Reduced 1.86%	94,697 $1.06 Million
Q2 2024 Aug 01, 2024	BUY	$10.58 - $15.61 $155,123 - $228,873	14,662 Added 17.92%	96,488 $1.04 Million
Q1 2024 May 09, 2024	BUY	$14.14 - $19.59 $17,137 - $23,743	1,212 Added 1.5%	81,826 $1.22 Million
Q4 2023 Feb 08, 2024	BUY	$12.85 - $19.15 $19,493 - $29,050	1,517 Added 1.92%	80,614 $1.46 Million
Q3 2023 Nov 09, 2023	BUY	$14.58 - $20.15 $3,717 - $5,138	255 Added 0.32%	79,097 $1.37 Million
Q2 2023 Aug 08, 2023	BUY	$18.12 - $30.56 $1.43 Million - $2.41 Million	78,842 New	78,842 $1.43 Million
Q2 2022 Aug 11, 2022	SELL	$4.11 - $8.75 $93,983 - $200,086	-22,867 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$7.01 - $14.1 $3,666 - $7,374	523 Added 2.34%	22,867 $160,000
Q4 2021 Feb 10, 2022	SELL	$12.27 - $18.26 $5,104 - $7,596	-416 Reduced 1.83%	22,344 $302,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $28.98 $16,397 - $28,835	995 Added 4.57%	22,760 $384,000
Q2 2021 Aug 05, 2021	SELL	$28.05 - $37.69 $64,010 - $86,008	-2,282 Reduced 9.49%	21,765 $634,000
Q1 2021 May 06, 2021	BUY	$24.52 - $40.23 $338,326 - $555,093	13,798 Added 134.63%	24,047 $946,000
Q4 2020 Feb 10, 2021	BUY	$19.89 - $32.99 $203,852 - $338,114	10,249 New	10,249 $233,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $632M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Pliant Therapeutics, Inc. Transaction History